Alcohol consumption is a leading preventable cause of death in the U.S.  A JAMA cross-sectional study suggests that between 2015 and 2019, an estimated 1 in 8 total deaths among U.S. adults ages 20 to 64 were attributable to excessive alcohol use, including 1 in 5 deaths among adults ages 20 to 49. 

The European Medicines Agency’s (EMA's) safety committee (PRAC) has issued a recommendation that the use of oral JAK inhibitors (tofacitinib, baricitinib, upadacitinib and filgotinib) be limited to certain at-risk patients unless no other suitable treatment alternatives are available.

Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill. 

Today, Cardinal Health released its third edition of Rheumatology Insights, a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends

 Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE.

EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.

Newly released guidance for defining remission in rheumatoid arthritis (RA) is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.

Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritits (SpA) patients in England.

Population based study from Minnesota shows that the incidence of lupus nephritis (LN) in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates six times that of the general population.

Assessment of SpondyloArthritis international Society (ASAS) and EULAR have published their 2022 update and recommendations for the management of axial spondyloarthritis (axSpA).

On Friday October 21st the U.S. Food and Drug Administration approved upadacitinib (Rinvoq) for the treatment of active non-radiographic axial spondyloarthritis in patients with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor blocker therapy.

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.

Patients with rheumatologic conditions who developed breakthrough COVID-19 infection after vaccination were less likely to suffer long-term symptoms than unvaccinated but otherwise similar patients, researchers said.

Pregnancy in systemic lupus erythematosus (SLE) is fraught with problems of adverse pregnancy outcomes, more pregnancy loss and birth defects. Now a study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects.

In a recent analysis published in Arthritis & Rheumatology, people at risk for rheumatoid arthritis (RA) and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc). 

Add "hard rock" mining to the list of occupations associated with high rates of rheumatoid arthritis (RA), a new study indicated, with silica exposure the presumed malefactor.

In this week's special podcast, Dr. Jack Cush offers a primer on rheumatology clinical trials, answering the question: should you be involved in research and clinical trials in rheumatology?

A study from the Georgia Lupus Registry shows that systemic lupus erythematosus patients are at greatest risk for cardiovascular disease events between years 2 and 11 after diagnosis and higher in Black people or those with a discoid rash.

The results of a treat-to-target (T2T) combination therapy trial in patients with early rheumatoid arthritis (RA) show that if patients fail to respond initially, then a second, more intensified regimen can turn initial nonresponders into responders.

The American College of Rheumatology (ACR) and the Association of Rheumatology Professionals (ARP) proudly recognizes the recipients of its 2022 Master of the ACR and ARP designations, ACR Awards of Distinction, and ARP Awards of Merit and Appreciation.